These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 17312334)

  • 1. Variation in institutional review board responses to a standard, observational, pediatric research protocol.
    Mansbach J; Acholonu U; Clark S; Camargo CA
    Acad Emerg Med; 2007 Apr; 14(4):377-80. PubMed ID: 17312334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Institutional review board variability in minimal-risk multicenter urogynecology studies.
    Harvie HS; Lowenstein L; Omotosho TB; Sanses T; Molden S; Hardy J; Brubaker L;
    Female Pelvic Med Reconstr Surg; 2012; 18(2):89-92. PubMed ID: 22453318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of IRB requirements on a multicenter survey of prophylactic mastectomy outcomes.
    Greene SM; Geiger AM; Harris EL; Altschuler A; Nekhlyudov L; Barton MB; Rolnick SJ; Elmore JG; Fletcher S
    Ann Epidemiol; 2006 Apr; 16(4):275-8. PubMed ID: 16005245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review finds that multicenter studies face substantial challenges but strategies exist to achieve Institutional Review Board approval.
    Greene SM; Geiger AM
    J Clin Epidemiol; 2006 Aug; 59(8):784-90. PubMed ID: 16828670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Variability of the institutional review board process within a national research network.
    Khan MA; Barratt MS; Krugman SD; Serwint JR; Dumont-Driscoll M;
    Clin Pediatr (Phila); 2014 Jun; 53(6):556-60. PubMed ID: 24658908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variation in Institutional Review processes for a multisite observational study.
    Vick CC; Finan KR; Kiefe C; Neumayer L; Hawn MT
    Am J Surg; 2005 Nov; 190(5):805-9. PubMed ID: 16226962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulatory challenges: lessons from recent West Nile virus trials in the United States.
    Jester PM; Tilden SJ; Li Y; Whitley RJ; Sullender WM
    Contemp Clin Trials; 2006 Jun; 27(3):254-9. PubMed ID: 16603417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medical education research and IRB review: an analysis and comparison of the IRB review process at six institutions.
    Dyrbye LN; Thomas MR; Mechaber AJ; Eacker A; Harper W; Massie FS; Power DV; Shanafelt TD
    Acad Med; 2007 Jul; 82(7):654-60. PubMed ID: 17595560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variation in standards of research compensation and child assent practices: a comparison of 69 institutional review board-approved informed permission and assent forms for 3 multicenter pediatric clinical trials.
    Kimberly MB; Hoehn KS; Feudtner C; Nelson RM; Schreiner M
    Pediatrics; 2006 May; 117(5):1706-11. PubMed ID: 16651328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Approaches to facilitate institutional review board approval of multicenter research studies.
    Marsolo K
    Med Care; 2012 Jul; 50 Suppl():S77-81. PubMed ID: 22692264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Variation in institutional review board responses to a standard protocol for a multicenter clinical trial.
    Stair TO; Reed CR; Radeos MS; Koski G; Camargo CA;
    Acad Emerg Med; 2001 Jun; 8(6):636-41. PubMed ID: 11388939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The IRB challenge for practice-based research: strategies of the American Academy of Family Physicians National Research Network (AAFP NRN).
    Graham DG; Spano MS; Manning B
    J Am Board Fam Med; 2007; 20(2):181-7. PubMed ID: 17341755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Practical tips for working effectively with your institutional review board.
    Schwenzer KJ
    Respir Care; 2008 Oct; 53(10):1354-61. PubMed ID: 18812000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Invisible barriers to clinical trials: the impact of structural, infrastructural, and procedural barriers to opening oncology clinical trials.
    Dilts DM; Sandler AB
    J Clin Oncol; 2006 Oct; 24(28):4545-52. PubMed ID: 17008693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinician educators' experiences with institutional review boards: results of a national survey.
    Dyrbye LN; Thomas MR; Papp KK; Durning SJ
    Acad Med; 2008 Jun; 83(6):590-5. PubMed ID: 18520468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Institutional review board guidance on pediatric research: missed opportunities.
    Wolf LE; Zandecki J; Lo B
    J Pediatr; 2005 Jul; 147(1):84-9. PubMed ID: 16027701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time to institutional review board approval with local versus central review in a multicenter pragmatic trial.
    Neuman MD; Gaskins LJ; Ziolek T;
    Clin Trials; 2018 Feb; 15(1):107-111. PubMed ID: 28982261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review of multicenter studies by multiple institutional review boards: characteristics and outcomes for perinatal studies implemented by a multicenter network.
    Abramovici A; Salazar A; Edvalson T; Gallagher N; Dorman K; Tita A;
    Am J Obstet Gynecol; 2015 Jan; 212(1):110.e1-6. PubMed ID: 25088862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conducting research using the emergency exception from informed consent: the Public Access Defibrillation (PAD) Trial experience.
    Mosesso VN; Brown LH; Greene HL; Schmidt TA; Aufderheide TP; Sayre MR; Stephens SW; Travers A; Craven RA; Weisfeldt ML;
    Resuscitation; 2004 Apr; 61(1):29-36. PubMed ID: 15081178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ontario Cancer Research Ethics Board: lessons learned from developing a multicenter regional institutional review board.
    Saginur R; Dent SF; Schwartz L; Heslegrave R; Stacey S; Manzo J
    J Clin Oncol; 2008 Mar; 26(9):1479-82. PubMed ID: 18349399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.